Comparison between obese and non-obese nonalcoholic fatty liver disease
- PMID: 36472052
- PMCID: PMC10029940
- DOI: 10.3350/cmh.2022.0350
Comparison between obese and non-obese nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associated with overnutrition and obesity, although it may be also found in lean or non-obese individuals. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all-cause mortality, liver-related mortality, and cardiovascular mortality among non-obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake, and unaccounted weight changes over time. Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass index increases in the obese state. Overall, non-invasive tests, such as the Fibrosis-4 index, NAFLD fibrosis score, and liver stiffness measurement, perform better in lean or non-obese patients compared to obese patients. Lifestyle intervention works in non-obese patients, and less amount of weight loss may be required to achieve similar results compared to obese patients. Pharmacological therapy in non-obese NAFLD patients may require special consideration and a different approach compared to obese patients.
Keywords: Lean; Non-obese; Nonalcoholic fatty liver disease.
Conflict of interest statement
Wah-Kheong Chan has served as a consultant or advisory board member for Roche, Abbvie, Boehringer Ingelheim and Novo Nordisk; and a speaker for Viatris and Hisky Medical.
Figures

Comment in
-
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?Clin Mol Hepatol. 2023 Apr;29(2):377-380. doi: 10.3350/cmh.2023.0061. Epub 2023 Mar 9. Clin Mol Hepatol. 2023. PMID: 36907573 Free PMC article. No abstract available.
Similar articles
-
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26. Clin Gastroenterol Hepatol. 2017. PMID: 28554682
-
The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.J Gastroenterol Hepatol. 2022 Oct;37(10):1901-1910. doi: 10.1111/jgh.15936. Epub 2022 Jul 13. J Gastroenterol Hepatol. 2022. PMID: 35790343
-
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease.Gut Liver. 2022 Mar 15;16(2):290-299. doi: 10.5009/gnl210084. Gut Liver. 2022. PMID: 34238770 Free PMC article.
-
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12. Lancet Gastroenterol Hepatol. 2020. PMID: 32413340
-
Special Population: Lean Nonalcoholic Fatty Liver Disease.Clin Liver Dis. 2023 May;27(2):451-469. doi: 10.1016/j.cld.2023.01.011. Epub 2023 Feb 26. Clin Liver Dis. 2023. PMID: 37024218 Review.
Cited by
-
Triglycerides Mediate the Influence of Body Mass Index on Non-Alcoholic Fatty Liver Disease in a Non-Obese Chinese Population with Normal Low-Density Lipoprotein Cholesterol Levels.Obes Facts. 2024;17(2):191-200. doi: 10.1159/000536447. Epub 2024 Jan 24. Obes Facts. 2024. PMID: 38266508 Free PMC article.
-
Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study.Hepatol Int. 2025 Feb;19(1):181-190. doi: 10.1007/s12072-024-10737-8. Epub 2024 Oct 12. Hepatol Int. 2025. PMID: 39394385
-
Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate-Based Nanoparticle.Pharmaceutics. 2025 Apr 7;17(4):480. doi: 10.3390/pharmaceutics17040480. Pharmaceutics. 2025. PMID: 40284475 Free PMC article.
-
From MASLD to HCC: What's in the middle?Heliyon. 2024 Jul 31;10(15):e35338. doi: 10.1016/j.heliyon.2024.e35338. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170248 Free PMC article. Review.
-
Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China.Eur J Med Res. 2025 Feb 25;30(1):137. doi: 10.1186/s40001-025-02373-1. Eur J Med Res. 2025. PMID: 40001266 Free PMC article. Review.
References
-
- Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70–85. - PubMed
-
- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. - PubMed
-
- Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:2809–2817. e28. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical